ANGO News and Press, AngioDynamics Inc. From 01/07/21

AngioDynamics, Inc. (ANGO) Q2 2021 Earnings Conference Call January 7, 2021 8:00 AM ET Company Participants Jim Clemmer - President and Chief Executive Officer Steve Trowbridge - Executive Vice President and Chief Financial Officer Conference Call Participants Jayson Bedford - Raymond James M...

Image source: The Motley Fool. AngioDynamics Inc (NASDAQ: ANGO) Q2 2021 Earnings Call Jan 7, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: AngioDynamics Inc (ANGO) Q2 2021 Earnings Call Transcript

The following slide deck was published by AngioDynamics, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: AngioDynamics, Inc. 2021 Q2 - Results - Earnings Call Presentation

AngioDynamics (ANGO): FQ2 Non-GAAP EPS of $0.01 beats by $0.03; GAAP EPS of -$0.11 beats by $0.01.Revenue of $72.8M (+4.0% Y/Y) beats by $5.47M.FY 2021 guidance: net sales to be $278M-284M vs. consensus of $281.5M and adjusted earnings per share to be $0.00-$0.05 vs. consensus of $0.02.Press ...

Fiscal 2021 Second Quarter Highlights Net sales of $72.8 million increased 4.0% compared to the prior-year quarter Gross margin declined 410 basis points year over year to 55.2% GAAP loss per share of $0.11 and adjusted earnings per share of $0.01 ...

AngioDynamics (NASDAQ:ANGO) is scheduled to announce Q2 earnings results on Thursday, January 7th, before market open.The consensus EPS Estimate is -$0.02 (-133.3% Y/Y) and the consensus Revenue Estimate is $67.33M (-3.8% Y/Y).Over the last 2 years, ANGO has beaten EPS estimates 63% of the ti...

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice Presid...

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice Presid...

AngioDynamics is in a "prove it" phase, now having to plea their case in the investment debate through performance this year. We would note that several COVID-related headwinds remain, and management sees a 10-15% COVID-19 headwind to total sales this year. We feel the cash positi...

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the second quarter of fiscal year 2021 before the market ope...